

TO: Commissioner for Patents, Washington, DC 20231.
If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/593217

WPG/Reg/PTO/15 SEP 2005

PTO/SB/08B (02-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	Not Yet Known
Filing Date	Herewith
First Named Inventor	King, et al.
Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	891-A-PCT-US

Sheet 2

of 2

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/G.K./	1	PCT International Search Report for VION Pharmaceuticals, et al., Int'l Application No. PCT/US2005/010152, Filed March 25, 2005, Dated March 21, 2006	
/G.K./	2	LEE, et al., "Toxicological evaluation of 1,2 bis("methylsulfonyl)-1-(2-chloroethyl)-2 (methylaminocarbonyl) hydrazine (VNP40101M), novel alkylating Agent with Potential Antitumor Activity, with Intravenous Administration in Rats and Dogs", International Journal of Toxicology, Vol. 23, Pages 23-39 (2002)	
/G.K./	3	Ishiguro, et al., "Role of O-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine", Mol Cancer Ther, Vol. 4 (11), Pages 1755-1763 (2005)	
/G.K./	4	Murren, et al., "A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer", Investigational New Drugs, Vol 23, Pages 123-135 (2005)	
/G.K./	5	Giles, et al., "A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia.", Clinical Cancer Research, Vol. 10, Pages 2908-2917 (2004)	
/G.K./	6	Rice, et al., "Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNU.", Biochemical Pharmacology, Vol. 69, Pages 1463-1472 (2005)	

Examiner
Signature

/Ganapathy Krishnan/

Date
Considered

05/08/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.